Welcome to our dedicated page for RVL Pharmaceuticals plc news (Ticker: RVLP), a resource for investors and traders seeking the latest updates and insights on RVL Pharmaceuticals plc stock.
RVL Pharmaceuticals plc (symbol: RVLP) is a specialty pharmaceutical company that focuses on the commercialization of innovative healthcare solutions. The company is best known for its flagship product, UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is the first and only non-surgical treatment approved by the U.S. Food and Drug Administration (FDA) for acquired blepharoptosis, commonly known as droopy or low-lying eyelids, in adults.
Previously known as Osmotica Pharmaceuticals, RVL Pharmaceuticals leverages its extensive experience in drug delivery technologies with a particular emphasis on neurology-based therapies. The company's portfolio includes products in various stages of development aimed at treating movement disorders such as multiple sclerosis (MS) and Parkinson's disease. Additionally, RVL employs its well-established Osmodex® technologies to develop drug candidates for partner companies, effectively broadening its market and impact within the pharmaceutical industry.
In recent corporate developments, RVL Pharmaceuticals successfully passed a resolution at their Annual General Meeting (AGM) regarding the approval of a waiver of offer obligations under Rule 9 of the Rules. This enables the acquisition of ordinary shares by the company’s major shareholders and certain members of its management team without the obligation to make a general offer to other shareholders. This strategic move was supported by a significant majority of independent shareholders.
RVL Pharmaceuticals maintains a proactive approach in engaging with investors and media, regularly disseminating updates and holding conference calls to discuss financial results and other significant milestones. For instance, the upcoming conference call to present the second quarter 2023 financial results is scheduled for August 14, 2023.
Furthermore, the company has recently undertaken a reorganization process to better align its operational structure with its strategic goals. Detailed information about this reorganization, including court filings and other relevant documents, can be accessed through the RVL Pharmaceuticals restructuring site.
With a commitment to advancing healthcare through innovation, RVL Pharmaceuticals plc continues to enhance its market position and aims to deliver substantial value to its shareholders and stakeholders.
RVL Pharmaceuticals reported Q2 2022 UPNEEQ® net product sales of $8.4 million, a 42% increase from Q1. The company experienced a 16% rise in unique pharmacy-paid prescribers, reaching approximately 15,000. Despite total revenues dropping by $3.1 million year-over-year due to the absence of licensing revenue, UPNEEQ sales showed significant growth, up $6.9 million from the prior year. Net loss decreased to $(12.1 million) from $(22.0 million). Cash reserves at quarter-end were $27.4 million, supported by recent financing efforts.
RVL Pharmaceuticals has secured up to $68.9 million in financing through equity and non-dilutive debt, significantly bolstering its financial position. The deal includes $43.9 million in immediate funding from a private placement of shares and $20.0 million in second tranche senior secured notes, with an additional $25.0 million available contingent on revenue targets. This financing supports the commercialization of UPNEEQ, a treatment for low-lying eyelids, with positive feedback driving sales growth.
RVL Pharmaceuticals plc will announce its second quarter 2022 financial results on August 11, 2022, before U.S. markets open. This announcement will include a commercial update regarding UPNEEQ, the first FDA-approved non-surgical treatment for acquired blepharoptosis. CEO Brian Markison and other executives will host a conference call at 8:30 a.m. ET to discuss the results and answer questions. Investors can register for the call via a provided link, enhancing security and reducing wait times.
RVL Pharmaceuticals (Nasdaq: RVLP) announced expected second quarter 2022 net product sales of $8.4 million for UPNEEQ, a 42% increase from the previous quarter. Cumulative orders from 2,200 medical aesthetics practices reflect a 100% growth since Q1 2022. The company maintains its guidance for fourth quarter 2022 sales between $20 million and $25 million. The preliminary data, which is unverified, underscores the potential of UPNEEQ in the aesthetics market.
RVL Pharmaceuticals plc (NASDAQ: RVLP) held its Annual General Meeting on June 16, 2022, where independent shareholders approved a waiver under Rule 9 of the Irish Takeover Rules. The resolution, which saw 28,894,940 votes in favor and 1,340,770 against, allows for potential increases in shareholding by specific parties if the company issues up to 17 million new ordinary shares. With this, affected parties can raise their ownership percentage without triggering a mandatory offer to other shareholders. RVL focuses on the commercialization of UPNEEQ®.
RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that CEO Brian Markison will present at two significant conferences. The H.C. Wainwright Global Investment Conference is scheduled for May 24, 2022, at 11:00 a.m. ET, in Miami Beach, FL, with a webcast available here. Another presentation will take place at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 p.m. ET, in New York City, NY, which can be accessed here.
RVL Pharmaceuticals plc (Nasdaq: RVLP) reported a strong first quarter of 2022, achieving total revenues of $21.4 million, a significant increase from $0.9 million year-over-year. Notably, UPNEEQ net product sales reached $5.9 million, reflecting a 90% growth over the previous quarter. The company received $15.5 million from its Santen License Agreement. Despite a net loss of $(6.8) million, down from $(13.8) million in 2021, RVL reaffirmed its guidance for UPNEEQ sales in Q4 2022 at $20 to $25 million. The recent awards for UPNEEQ also highlight its market recognition.
RVL Pharmaceuticals plc (Nasdaq: RVLP) is set to release its first quarter 2022 financial results and provide a commercial update on May 12, 2022, before U.S. markets open. The conference call will feature CEO Brian Markison and other executives discussing key financial metrics and business strategies. RVL focuses on underserved patient populations in ocular and medical aesthetics, currently commercializing UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution) 0.1%. Investors can access the live webcast and replay on the company’s website.
FAQ
What is the market cap of RVL Pharmaceuticals plc (RVLP)?
What is RVL Pharmaceuticals plc known for?
What are the company's core areas of focus?
What recent corporate development took place at the AGM?
How does RVL Pharmaceuticals engage with investors and media?
What is the significance of UPNEEQ®?
What technologies does RVL Pharmaceuticals utilize in its drug development?
When is the next conference call scheduled?
What is the purpose of the ongoing reorganization process?
Where can I find more information about the reorganization?
Who should I contact for investor and media inquiries?
